Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential

Affiliations

¹ Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA.
² Department of Medicine, Creighton University Arizona Health Education Alliance, Phoenix, Az, USA.
³ Tufts University School of Medicine, Boston, MA, USA.
⁴ Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA.
⁵ Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USA.
⁶ Hypertrophic Cardiomyopathy Center, Cardiac Catheterization Laboratory, Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USA.

Editorial

Shiavax J Rao et al. Expert Opin Investig Drugs. 2023 Jan.

. 2023 Jan;32(1):1-4.

doi: 10.1080/13543784.2023.2166825. Epub 2023 Jan 12.

¹ Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA.
² Department of Medicine, Creighton University Arizona Health Education Alliance, Phoenix, Az, USA.
³ Tufts University School of Medicine, Boston, MA, USA.
⁴ Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA.
⁵ Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USA.
⁶ Hypertrophic Cardiomyopathy Center, Cardiac Catheterization Laboratory, Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USA.

No abstract available

Comment on

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C, Li W, Sterling L, Lampl K, Edelberg JM, Sehnert AJ, Nissen SE. Desai MY, et al. J Am Coll Cardiol. 2022 Jul 12;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048. J Am Coll Cardiol. 2022. PMID: 35798455 Clinical Trial.